A medically supervised GLP-1 program may help by supporting: Appetite control Earlier fullness during meals Reduced cravings for some patients Smaller portion sizes Better meal consistency Support for reduced calorie intake Improved structure during a weight loss program These medications should be used with medical guidance
this is in contrast to native GLP-1 which is also capable of simultaneously activating the beta-arrestin pathway [44]
In summary, the GLP-1 receptor remains an interesting and noteworthy target for the pharmacotherapy of central nervous system diseases, not only those related to neurodegeneration and substance abuse, but GLP-1RA drugs may also prove effective as adjunctive therapies in the treatment of mood disorders such as depression
"The FDA boxed warning tied to GLP-1 medications is specific to a rare cancer called medullary thyroid carcinoma
doi:10.1038/s41392-024-01951-9 Uusitupa M, Khan TA, Viguiliouk E, et al
The SELECT trial in non-diabetic patients with cardiovascular disease demonstrated a 20% reduction in heart attacks and strokes
